Edgewise (EWTX) CMO Joanne M. Donovan Receives Option Award

What Happened

• Joanne M. Donovan, Chief Medical Officer of Edgewise Therapeutics (EWTX), received a grant of options covering 65,000 shares on 2026-08-12. The corrected exercise price is $43.56 per share (the original filing mistakenly listed $0.00). Exercising all options would require about $2,831,400 (65,000 × $43.56). This is a compensation grant (award), not an immediate purchase or sale of shares.

Key Details

• Transaction date: 2026-08-12 (Amended Form 4 filed 2026-08-17 to correct exercise price).
• Grant type: Derivative/option award (reported under code A).
• Shares/options granted: 65,000.
• Correct exercise price: $43.56 per share (originally reported as $0.00 due to a clerical error).
• Vesting: 1/48th of the options vest each month beginning September 12, 2026 (i.e., 48-month monthly vesting), contingent on continued service.
• Shares owned after transaction: Not specified in the provided excerpt.
• Filing note: This is an amended filing correcting the exercise price; the amendment was filed five days after the grant date.

Context

• This is an option grant (compensation) rather than a market purchase or sale; it signals compensation alignment rather than an immediate insider bet. The exercise price equals fair market value on the grant date per the amendment. The award vests monthly over four years, so the options become exercisable gradually subject to continued service.